PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from China

Selling into Europe as a biologics and biosimilars maker from China

Launch your biologic in Europe on the date you planned, not months after.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • China, Biologics and biosimilarswho it is written for

Why this training matters

The European Medicines Agency sends a list of questions on your Module 3, and nobody on the team can say which Chinese site record answers it. The clock stops while you search. Your sales team waits with a launch plan and a tender date that does not move.

What changes after this course

Your team files each section in the right place, answers questions in one voice and meets inspectors with the records open. You hold a certificate per learner and a training record for each person, ready for any partner or auditor who asks.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team stops guessing where each document sits in Modules 1 to 5 of the Common Technical Document. They choose the route under Regulation (EC) No 726/2004, use Article 10(4) of Directive 2001/83/EC where it applies, and send a file that answers the assessors' questions before they are asked. The reply to a list of questions leaves your desk in one voice.

A quality assurance lead walks the Chinese site through EudraLex Volume 4 before the inspector does. Gaps in data integrity, cleanroom records or batch files get closed on your schedule. When your European Qualified Person asks for the batch file under Annex 16, it is already complete, and release does not wait.

In clinical development, the comparability plan is right from the first meeting. Your clinical team chooses the European reference product, sets the quality ranges, and decides what a small difference means before a reviewer raises it. Your safety team writes the pharmacovigilance system master file and the risk management plan, and reports reactions through EudraVigilance on time.

Commercial staff answer the question that stalls a launch: where, when and at what price. They read a supplementary protection certificate, price with external reference pricing in mind, and speak to prescribers and key opinion leaders inside the codes of practice. Cold chain records and Falsified Medicines Directive pack features are checked before the first pallet leaves China.

Who needs this training

  • Regulatory Affairs Manager

    The day the assessors' list of questions arrives, you must find which Module 3 section caused it and who answers it. This course gives you that answer before the file goes in.

  • Quality Assurance Lead

    The week before a European inspector visits the Chinese site, a mock audit shows an EudraLex Volume 4 gap and the batch file is still incomplete. You close it in time.

  • Clinical Development Manager

    The design review for the comparability study, where someone must fix the reference product and acceptance ranges that a European reviewer will later accept or reject.

  • Business Development Director

    The partner negotiation where a supplementary protection certificate date decides whether the contract starts a launch or sits dormant until protection ends.

  • Market Access Manager

    The pricing meeting for a national payer, where the price you quote in one country becomes the reference point in the next, and a health technology assessment body wants evidence.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: China

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Place each document of a biologic dossier in the correct section of Modules 1 to 5 of the Common Technical Document.
  2. Decide whether a product follows the biosimilar route under Article 10(4) of Directive 2001/83/EC or the full new biologic route.
  3. Run a mock inspection of a Chinese site against EudraLex Volume 4 and list the gaps in writing.
  4. Draft the outline of a pharmacovigilance system master file and route adverse reaction reports into EudraVigilance.
  5. Check a supply route against the Falsified Medicines Directive pack features and the cold chain expectations of Good Distribution Practice.
  6. Classify a post-approval change as Type IA, Type IB or Type II under Regulation (EC) No 1234/2008.
  7. Read a supplementary protection certificate and name the earliest lawful launch date for a given country.

What the company gets

  • Your dossier reaches the European Medicines Agency with every document in its place, so the review clock is spent on science and not on missing files.
  • Your Chinese site meets an inspector with records ready and a straight answer to each question under EudraLex Volume 4.
  • Your launch date comes from a checked supplementary protection certificate and a patent review, so the first order ships on a date your legal team can defend.
  • Each learner holds a certificate, and you hold a per-person training record that shows who completed each module and answered its questionnaire.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Size up the European market for your biosimilars and biologics

    • How to pick your first European countries from originator sales and tender timing, not guesswork.
    • How to read an incumbent's pricing and portfolio so your launch plan has an answer before the first tender.
    • What to do when the molecule you planned around already has several biosimilars on the shelf.
  2. 2Choose the route to European marketing authorization for your biologic

    • How to tell in one meeting whether your product takes the biosimilar route or the full new biologic route.
    • Why Article 10(4) of Directive 2001/83/EC lets you lean on the originator's data, and where it stops.
    • What to do when the review clock stops for a list of questions and your team must answer in one voice.
  3. 3Compile a Common Technical Document the reviewer can follow

    • How to place each document in Modules 1 to 5 so the reviewer never has to hunt for a study report.
    • The Module 3 quality sections where a biologic file invites questions, and how to close them first.
    • Why a clear Module 2 summary saves your team a round of questions from the assessors.
  4. 4Pass your European Good Manufacturing Practice inspections

    • How to walk your Chinese plant through EudraLex Volume 4 the way an inspector will, room by room.
    • Which data integrity records to have ready so an inspector's first request takes minutes to answer.
    • What to do when your mock audit finds a gap shortly before the inspector arrives.
  5. 5Design comparability studies that prove your biosimilarity

    • How to set acceptance ranges for quality attributes before the first comparison batch is made.
    • Why the European reference product you buy decides whether your comparison is read as valid.
    • What to do when the data shows a small difference from the reference product, and how to explain it.
  6. 6Set up your European pharmacovigilance system master file

    • How to build a pharmacovigilance system master file that an inspector can follow from the first page.
    • How to route an adverse reaction report into EudraVigilance within the time the rules allow.
    • Why the risk management plan must be ready at submission, and what goes into it.
  7. 7Price your biologics for diverse European reimbursement systems

    • What a health technology assessment body asks a biosimilar maker, and the answers to prepare in advance.
    • How to build one value story that a national payer and a hospital tender committee can both accept.
    • Why a low price in one country can follow you into the next through external reference pricing.
  8. 8Time your European market entry around patent expirations

    • How to read a supplementary protection certificate and find the date your launch can legally start.
    • How to check for patent risk in each country before you ship, so no injunction stops your first order.
    • When to file, when to wait, and when a settlement with the originator beats a court case.
  9. 9Sell your biosimilars to European prescribers who ask hard questions

    • How to answer a consultant who asks why she should switch a stable patient to your biosimilar.
    • What the 2022 European statement on biosimilar interchangeability lets you say to a prescriber.
    • Why a hospital pharmacist and a rheumatologist need different answers from your sales representative.
  10. 10Ship your biologics through European supply chains intact

    • How to prove to a wholesaler that your product stayed in range from Chinese plant to European pharmacy.
    • The Falsified Medicines Directive pack features: a unique identifier and an anti-tampering device.
    • When a distribution partner makes sense and when your own European entity protects you better.
  11. 11Build trust with European key opinion leaders and patients

    • How to find the patient groups whose position papers shape what a guideline committee reads.
    • What the codes of practice on contact with healthcare professionals let you offer, and what they forbid.
    • Why a Chinese manufacturer earns trust faster by opening its quality data than by adding sales visits.
  12. 12File variations under Regulation (EC) No 1234/2008 after approval

    • How to classify a process change as Type IA, Type IB or Type II before you file anything.
    • What data to attach when you move a manufacturing step to a new site, so the variation is not sent back.
    • What to do when a new European guideline changes what your approved file must show.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for China, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team